Literature DB >> 34185242

Psychometric utility of the international HIV dementia scale and Montreal Cognitive Assessment in HIV-associated asymptomatic neurocognitive impairment.

Stephen L Aita1, Quanhathai Kaewpoowat2,3,4, Saowaluck Yasri3, Amaraporn Rerkasem4, Kittipan Rerkasem4,5, Janejit Choovuthayakorn6, Somsanguan Ausayakhun6, Kevin Robertson7, Robert M Roth1, Nathaniel M Robbins8.   

Abstract

There is a growing need for brief screening measures for HIV Associated Neurocognitive Disorders (HAND). We compared two commonly used measures (the Montreal Cognitive Assessment [MoCA] and the International HIV Dementia Scale [IHDS]) in their ability to identify asymptomatic HAND (i.e., asymptomatic neurocognitive impairment [ANI]). Participants included 74 Thai PLWH: 38 met Frascati criteria for ANI and 36 were cognitively normal (CN). Participants completed Thai language versions of the MoCA (MoCA-T) and IHDS, and a validated neurocognitive battery. We examined between-group differences for MoCA-T and IHDS total scores, and scale subcomponents. We also conducted receiver operating characteristic (ROC) analyses to determine the ability of the MoCA-T and IHDS to discriminate between CN and ANI groups, and compared their area under the curve (AUC) values. Results revealed lower MoCA-T total score, as well as the Visuospatial/Executive and Delayed Recall subtask scores, in the ANI relative to CN group. Groups did not differ on the IHDS. For ROC analyses, the MoCA-T, but not the IHDS, significantly differentiated the ANI from CN group, and there was a significant difference in AUC values between the MoCA-T (AUC = .71) and IHDS (AUC = .56). Sensitivity and specificity statistics were poor for both screening measures. These data indicate while the MoCA-T functions better than the IHDS in detecting Thai PLWH with ANI, the mildest form of HAND, neither cognitive screener, showed strong utility. Our findings reflect the limited efficacy of common screening measures in detecting subtler cognitive deficits among Thai PLWH, and highlight the need for better screening tools.
© 2021. Journal of NeuroVirology, Inc.

Entities:  

Keywords:  Cognitive Impairment; HIV; HIV Dementia; IHDS; MoCA; Neuropsychology

Mesh:

Year:  2021        PMID: 34185242     DOI: 10.1007/s13365-021-00991-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  30 in total

1.  Validity of two scales in identifying HIV-associated dementia.

Authors:  J P Berghuis; K K Uldall; B Lalonde
Journal:  J Acquir Immune Defic Syndr       Date:  1999-06-01       Impact factor: 3.731

2.  Using MoCA-Thai to evaluate cognitive impairment in patients with schizophrenia.

Authors:  Suwanna Arunpongpaisal; Akekalak Sangsirilak
Journal:  J Med Assoc Thai       Date:  2013-07

3.  Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard.

Authors:  Henraya F Davis; Richard L Skolasky; Ola A Selnes; David M Burgess; Justin C McArthur
Journal:  AIDS Read       Date:  2002-01

4.  Self-reported awareness of performance in dementia.

Authors:  David P Graham; Mark E Kunik; Rachelle Doody; A Lynn Snow
Journal:  Brain Res Cogn Brain Res       Date:  2005-09

5.  The HIV Dementia Scale: predictive power in mild dementia and HAART.

Authors:  Kara Anne Bottiggi; Jason J Chang; Frederick A Schmitt; Malcolm J Avison; Yunanan Mootoor; Avindra Nath; Joseph R Berger
Journal:  J Neurol Sci       Date:  2007-05-04       Impact factor: 3.181

Review 6.  The Lawton instrumental activities of daily living scale.

Authors:  Carla Graf
Journal:  Am J Nurs       Date:  2008-04       Impact factor: 2.220

7.  The Montreal Cognitive Assessment-Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low-Educated Elderly Adults.

Authors:  Parunyou Julayanont; Sookjaroen Tangwongchai; Solaphat Hemrungrojn; Chawit Tunvirachaisakul; Kammant Phanthumchinda; Juntanee Hongsawat; Panida Suwichanarakul; Saowaluck Thanasirorat; Ziad S Nasreddine
Journal:  J Am Geriatr Soc       Date:  2015-12-09       Impact factor: 5.562

8.  Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings.

Authors:  K Blackstone; D J Moore; D R Franklin; D B Clifford; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; R J Ellis; J H Atkinson; I Grant; R K Heaton
Journal:  Clin Neuropsychol       Date:  2012-06-18       Impact factor: 3.535

9.  Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients.

Authors:  M A M Janssen; M Bosch; P P Koopmans; R P C Kessels
Journal:  J Neurovirol       Date:  2015-02-13       Impact factor: 2.643

10.  HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART.

Authors:  Tanya C Do; Stephen J Kerr; Anchalee Avihingsanon; Saowaluk Suksawek; Supalak Klungkang; Taweesak Channgam; Christoph C Odermatt; Wirach Maek-A-Nantawat; Kiat Ruxtungtham; Jintanat Ananworanich; Victor Valcour; Peter Reiss; Ferdinand W Wit
Journal:  J Virus Erad       Date:  2018-01-01
View more
  2 in total

1.  Lenalidomide Improves Cognitive Function and Reduces Immune Reconstitution Inflammatory Syndrome in HIV-1-Related Cryptococcal Meningitis.

Authors:  Ran Tao; Xiaorong Peng; Xiang Liu; Junwei Su; Guanjing Lang; Ying Huang; Yafei Zhang; Biao Zhu
Journal:  J Inflamm Res       Date:  2022-05-10

2.  Neurocognitive performance and quality of life of older adults with HIV on antiretroviral treatment in Northern Thailand.

Authors:  Linda Aurpibul; Patumrat Sripan; Arunrat Tangmunkongvorakul; Wilawan Chaikan; Saowalak Sarachai; Kriengkrai Srithanaviboonchai
Journal:  J Int AIDS Soc       Date:  2022-09       Impact factor: 6.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.